World's Best Scientists 2026 revealed!
Benoît Van den Eynde

Benoît Van den Eynde

D-Index & Metrics

Immunology

D-Index
78
Citations
24519
World Ranking
1740
National Ranking
23

Medicine

D-Index
78
Citations
24578
World Ranking
17976
National Ranking
227

Benoît Van den Eynde publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Benoît Van den Eynde sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 260 publications — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Benoît Van den Eynde D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Benoît Van den Eynde sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 78 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Benoît Van den Eynde is affiliated with Ludwig Cancer Research in Belgium. Their research spans multiple areas within the biomedical sciences, focusing primarily on medicine, immunology, and molecular biology.

The main fields of study of Benoît Van den Eynde include:

  • Medicine
  • Immunology and Microbiology
  • Biochemistry, Genetics and Molecular Biology

Subfields of study feature a concentration in oncology and immunology, with additional work in molecular biology and biological psychiatry. Specific subfields include:

  • Oncology
  • Immunology
  • Molecular Biology
  • Biological Psychiatry
  • Psychiatry and Mental Health

The primary research topics covered in Van den Eynde's work focus on immune mechanisms and cancer therapies with detail on immune responses and cell function. Major topics include:

  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • CAR-T Cell Therapy Research
  • Tryptophan and Brain Disorders
  • Cancer, Stress, Anesthesia, and Immune Response
  • Ubiquitin and Proteasome Pathways

Recent publications illustrate the diversity and scope of Van den Eynde's research contributions. Selected recent papers include:

  • Preclinical murine tumor models: A structural and functional perspective, 2020, eLife
  • Tumour immune rejection triggered by activation of α2-adrenergic receptors, 2023, Nature
  • Systemic tryptophan homeostasis, 2022, Frontiers in Molecular Biosciences
  • Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression, 2023, Journal for ImmunoTherapy of Cancer
  • Functional Differences between Proteasome Subtypes, 2022, Cells

Benoît Van den Eynde frequently collaborates with several co-authors, reflecting a network of scientific partnerships. Frequent co-authors include:

  • Jingjing Zhu
  • Stefan Naulaerts
  • Vincent Stroobant
  • Carol S. Leung
  • Nathalie Vigneron

The scientist's work is regularly published in journals emphasizing cancer immunotherapy and translational research. Frequent publication venues include:

  • Journal for ImmunoTherapy of Cancer
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cancer Immunology Research
  • Zenodo (CERN European Organization for Nuclear Research)
  • Science Translational Medicine

Best Publications

  • Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

    Catherine Uyttenhove;Luc Pilotte;Ivan Théate;Ivan Théate;Vincent Stroobant

  • Tumor-antigens recognized by T-lymphocytes

    Thierry Boon;Jean-Charles Cerottini;Benoît Van den Eynde;Pierre van der Bruggen

  • Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

    Pierre G. Coulie;Benoît J. Van den Eynde;Pierre van der Bruggen;Thierry Boon

  • HUMAN T CELL RESPONSES AGAINST MELANOMA

    Thierry Boon;Pierre G Coulie;Benoît J Van den Eynde;Pierre van der Bruggen

  • T cell defined tumor antigens

    Benoît J Van den Eynde;Pierre van der Bruggen

  • Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion.

    Michael Platten;Wolfgang Wick;Benoît J. Van den Eynde;Benoît J. Van den Eynde

  • Tumor antigens recognized by T cells

    Thierry Boon;Pierre G. Coulie;Benoît Van den Eynde

  • Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase

    Luc Pilotte;Pierre Larrieu;Vincent Stroobant;Didier Colau

  • Classification of current anticancer immunotherapies

    Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué

  • Tumor-specific shared antigenic peptides recognized by human T cells

    Pierre van der Bruggen;Yi Zhang;Pascal Chaux;Vincent Stroobant

  • Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells.

    Sandra Morel;Frédéric Lévy;Odile Burlet-Schiltz;Francis Brasseur

  • An Antigenic Peptide Produced by Peptide Splicing in the Proteasome

    Nathalie Vigneron;Vincent Stroobant;Jacques Chapiro;Annie Ooms

  • Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

    Abhishek D. Garg;Lorenzo Galluzzi;Lionel Apetoh;Lionel Apetoh;Thais Baert

  • Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues

    Ivan Théate;Ivan Théate;Nicolas van Baren;Nicolas van Baren;Luc Pilotte;Luc Pilotte;Pierre Moulin

  • Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape

    Abhishek D. Garg;Pierre G. Coulie;Benoit J. Van den Eynde;Patrizia Agostinis

  • Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules

    Benoît Guillaume;Jacques Chapiro;Vincent Stroobant;Didier Colau

  • Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome

    Benoı̂t J Van den Eynde;Sandra Morel

  • An antigen produced by splicing of noncontiguous peptides in the reverse order

    Edus H. Warren;Edus H. Warren;Nathalie J. Vigneron;Nathalie J. Vigneron;Marc A. Gavin;Marc A. Gavin;Pierre G. Coulie

  • Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.

    Jingjing Zhu;Jingjing Zhu;Céline G. Powis de Tenbossche;Céline G. Powis de Tenbossche;Stefania Cané;Stefania Cané;Didier Colau;Didier Colau

  • Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases

    Véronique Corbière;Jacques Chapiro;Vincent Stroobant;Wenbin Ma

  • A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma.

    Béatrice Gaugler;Nathalie Brouwenstijn;Valérie Vantomme;Jean-Pierre Szikora

  • Reversal of Tumoral Immune Resistance by Inhibition of Tryptophan 2,3-Dioxygenase (TDO): Design, Synthesis and Preclinical Evaluation of a Novel TDO Inhibitor.

    Eduard Dolušić;Pierre Larrieu;Laurence Moineaux;Vincent Stroobant

Frequent Co-Authors

Pierre van der Bruggen
Pierre van der Bruggen Université Catholique de Louvain
Thierry Boon
Thierry Boon Ludwig Cancer Research
Vincent Stroobant
Vincent Stroobant Ludwig Cancer Research
Pierre Coulie
Pierre Coulie Université Catholique de Louvain
Johan Wouters
Johan Wouters University of Namur
Catherine Uyttenhove
Catherine Uyttenhove Ludwig Cancer Research
Francis Brasseur
Francis Brasseur Ludwig Cancer Research
Catia Traversari
Catia Traversari MolMed (Italy)
Moreno Galleni
Moreno Galleni University of Liège
Anne-Marie Schmitt-Verhulst
Anne-Marie Schmitt-Verhulst Centre d’Immunologie de Marseille-Luminy

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in immunology, pursuing related nursing degrees can open diverse career pathways in healthcare and research. Many students transition into specialized roles by enrolling in programs like the acute care certification for FNP, which enables nurse practitioners to provide advanced care for patients with complex conditions.

Faster degree options like the nurse practitioner accelerated program offer an efficient pathway to becoming a nurse practitioner, combining rigorous training with flexible online learning formats ideal for busy students or career changers.

For individuals without a nursing background, online ABSN programs for non nurses provide an accessible gateway into nursing. These accelerated programs streamline the path from a non-nursing degree to a nursing career, equipping graduates to contribute meaningfully in clinical and research immunology settings.

Additionally, those seeking less competitive options may find success with the easiest accelerated nursing programs to get into. These programs still maintain quality education and can serve as a stepping stone to advanced immunology-related roles.

Best Scientists Citing Benoît Van den Eynde

Trending Scientists

Recently Published Articles